1. Hills, CA., Kelland, L.R., Abel, G., Siracky, J., Wilson, A.P., and Harrap, K.R. Biological properties of ten ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 59:527–534, 1989.
2. Knox, R.J., Friedlos, F., Lydall, D.A., and Roberts, J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine (l,l-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46:1972–1979, 1986.
3. Cleare, M.J. Transition metal complexes in cancer chemotherapy. Coordination Chem. Rev. 12:349–405, 1974.
4. Eastman, A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Bio-chem. Pharmacol. 36:4177–4178, 1987.
5. Roberts, J.J. and Thomson, A.J. The mechanism of action of antitumor platinum compounds. Prog. Nucleic Acid Res. Mol. Biol. 22:71–139, 1979.